RGNX vs. HLVX, CRGX, HUMA, PROK, ITOS, IMTX, MESO, KYTX, CABA, and VALN
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include HilleVax (HLVX), CARGO Therapeutics (CRGX), Humacyte (HUMA), ProKidney (PROK), iTeos Therapeutics (ITOS), Immatics (IMTX), Mesoblast (MESO), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO (NASDAQ:RGNX) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.
REGENXBIO presently has a consensus target price of $38.64, indicating a potential upside of 159.48%. HilleVax has a consensus target price of $29.00, indicating a potential upside of 164.36%. Given HilleVax's stronger consensus rating and higher possible upside, analysts clearly believe HilleVax is more favorable than REGENXBIO.
REGENXBIO has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.
HilleVax has a net margin of 0.00% compared to REGENXBIO's net margin of -299.96%. HilleVax's return on equity of -56.18% beat REGENXBIO's return on equity.
88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 13.1% of REGENXBIO shares are owned by insiders. Comparatively, 71.1% of HilleVax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
REGENXBIO received 414 more outperform votes than HilleVax when rated by MarketBeat users. However, 100.00% of users gave HilleVax an outperform vote while only 65.84% of users gave REGENXBIO an outperform vote.
HilleVax has lower revenue, but higher earnings than REGENXBIO. HilleVax is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
In the previous week, HilleVax had 4 more articles in the media than REGENXBIO. MarketBeat recorded 9 mentions for HilleVax and 5 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.99 beat HilleVax's score of 0.56 indicating that REGENXBIO is being referred to more favorably in the media.
Summary
HilleVax beats REGENXBIO on 9 of the 17 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
